GeneDx (WGSWW) Stock Analysis

What GeneDx does

GeneDx Holdings Corp., through its various operational units, specializes in delivering genomics-driven diagnostic and informational solutions. Central to its services is Centrellis, an advanced health intelligence platform powered by artificial intelligence. This platform effectively merges digital technologies with AI capabilities, enabling researchers to process and interpret extensive clinical and genomic datasets to generate thorough health insights. The company provides genetic testing for diagnosis, a range of screening programs, and pertinent information, with a primary focus on pediatric conditions, uncommon diseases affecting both adults and children, and screening for inherited cancers. GeneDx Holdings Corp. was established in 2017 and its main offices are located in Stamford, Connecticut.

Key metrics

ETFs linked to WGSWW

Broad-market and Healthcare sector ETFs an investor holding GeneDx is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how WGSWW fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for GeneDx?

GeneDx trades under the ticker WGSWW on NASDAQ.

Which exchange is WGSWW listed on?

WGSWW is listed on NASDAQ.

What sector does GeneDx operate in?

GeneDx is classified in the Healthcare sector (Medical - Diagnostics & Research industry).

How can PortView help analyze WGSWW in a portfolio?

PortView shows WGSWW's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.